Natural killer cells (NK) as components of the innate immunity substantially contribute to anti-tumor immune responses, NK cell subpopulations can be defined on the basis of the relative expression of CD16 and CD56 markers. Earlier research demonstrated a dramatic reduction in the frequency of perip...
In RSA, the absolute number of CD69+cells significantly increased(P=0.02). Also, results showed significant increase in the absolute number of CD56+/CD69+ cells in RSA(P=0.04). Conclusion: The results suggested that the higher percentage of NK cells in peripheral blood of RSA patients ...
Absolute counts of total T-lymphocytes and related subsets (CD3 + CD4+, CD3 + CD8+, CD3 + CD4 + CD8 + DP, CD3 + CD4 − CD8 − DN), B-lymphocytes and NK-cells (CD16 + CD56+) were correlated with IL-6 (column A), CRP serum ...
NK 细胞555332HU CD3 FITC100T 557710HU CD16 ALEXA 647100T 555516HU CD56 PE100T DC552764HU HLA-DR PERCP-CY5.550T 560895HU CD11C APC25T 561050HU CD123 PE25T 565009HU CD80 BB51525T 560957HU CD86 PE25T 561960HU CD83 APC25T
CD45 was preferentially expressed by macrophage-like cells. MHC class I antigen was expressed by the vascular endothelium in both BBB-protected and BBB-deficient areas and was additionally present as a lattice-like network throughout the BBB-deficient parenchyma in all CVOs. The results suggest ...
Median LC30 was 400/μl, (range 10-3295) and 150/μl, (range 6-1005) for CD56+, CD16+ CD3- NK cells (NK30). Eighty-five patients (51±4%) survive (median 1392 days). Patients with LC30 above median had significantly (p < 0.002) faster neutrophil engraftment (18 vs.13 days)...
However, there was good correlation between NK cells from the apheresis product compared with ALC at day 15 post-ASCT (CD16+/CD56+/CD3-, r = 0.77). These data provide preliminary evidence that the number of re-infused autologous graft NK cells in the apheresis product significantly affect ...
The main lymphocyte subsets identified in the apheresis product were T cells and NK cells. There was no strong correlation between T or B cells from the apheresis product compared with the ALC at day 15 post-ASCT (CD3, r=0.21; CD4, r=0.32; CD8, r=0.39; and CD19, r=0.14). However...